Méndez-Toro A. Perspectives on monitoring and diagnosis of chemotherapy-induced cardiotoxicity. World J Clin Cases 2025; 13(34): 113256 [DOI: 10.12998/wjcc.v13.i34.113256]
Corresponding Author of This Article
Arnold Méndez-Toro, Professor, Department of Cardiology, Hospital Universitario Nacional de Colombia, Cl. 44 #59-75, Bogota 111321, Bogotá, Colombia. arnold.mendez@hun.edu.co
Research Domain of This Article
Oncology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 6, 2025 (publication date) through Dec 9, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Méndez-Toro A. Perspectives on monitoring and diagnosis of chemotherapy-induced cardiotoxicity. World J Clin Cases 2025; 13(34): 113256 [DOI: 10.12998/wjcc.v13.i34.113256]
Perspectives on monitoring and diagnosis of chemotherapy-induced cardiotoxicity
Arnold Méndez-Toro
Arnold Méndez-Toro, Department of Cardiology, Hospital Universitario Nacional de Colombia, Bogota 111321, Bogotá, Colombia
Author contributions: Méndez-Toro A is the sole author of this manuscript; He is responsible for the concept, intellectual content, literature search, manuscript preparation, manuscript editing, and manuscript review; He takes full responsibility for the integrity of the work as a whole and acts as the guarantor.
Conflict-of-interest statement: The author, Arnold Méndez-Toro, declares that he has no conflicts of interest, whether financial or non-financial, that could be perceived as influencing the content or conclusions of this manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arnold Méndez-Toro, Professor, Department of Cardiology, Hospital Universitario Nacional de Colombia, Cl. 44 #59-75, Bogota 111321, Bogotá, Colombia. arnold.mendez@hun.edu.co
Received: August 26, 2025 Revised: September 25, 2025 Accepted: November 17, 2025 Published online: December 6, 2025 Processing time: 104 Days and 8.3 Hours
Core Tip
Core Tip: The accurate identification and monitoring of chemotherapy-related cardiotoxicity demand inclusive patient selection and robust diagnostic strategies. Our study demonstrates that real-world cohorts often reflect local epidemiological patterns rather than exclusionary criteria, underscoring the need for comprehensive inclusion of both solid and hematologic malignancies. Retrospective designs, while valuable, may overlook subclinical conditions such as myocarditis and lack precise chemotherapy dose tracking. Integrating advanced imaging, standardized biomarker surveillance, and multicenter collaboration in prospective registries can close these gaps, enhance diagnostic certainty, and improve risk stratification. Such approaches will strengthen cardio-oncology practice and optimize long-term cardiovascular outcomes in cancer patients.
